Avalanche Biotechnologies Coverage Initiated by Analysts at Piper Jaffray (AAVL)
Stock analysts at Piper Jaffray started coverage on shares of Avalanche Biotechnologies (NASDAQ:AAVL) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating and a $39.00 price target on the stock. Piper Jaffray’s price objective suggests a potential upside of 27.79% from the company’s current price.
Separately, analysts at Jefferies Group initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set a “buy” rating and a $40.00 price target on the stock.
Shares of Avalanche Biotechnologies (NASDAQ:AAVL) opened at 30.52 on Monday. Avalanche Biotechnologies has a one year low of $22.00 and a one year high of $32.375. The stock has a 50-day moving average of $26.28 and a 200-day moving average of $26.28. The company’s market cap is $651.9 million.
Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.